Ixico Share Discussion Threads

[fillipe] 02/9/2015 11:05

Very low mkt cap...sub £5m. Ive taken a few more in the last couple of days.

f

[skinny] 28/8/2015 13:52

IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announced that it has been awarded a long-term contract from a leading global pharmaceutical company with a revenue value to IXICO of c. $1 million per year.

more...

[jondev] 20/7/2015 16:28

What's going on here? Shares in Ixico going up? How unusual, they normally go down . Does someone know something ?

[fillipe] 17/7/2015 16:21

IXI well in demand today.... + 8.8%.

Precious little stock showing on Level 2....just 7k shrs each side of the bid/ask, all spread over 4 mm's, some of whom show only 1000 shrs.

Easy to see how any strong whiff of demand will quickly send IXI much higher.

The best ask is now shown at 33p.

gla

f

[skinny] 29/6/2015 07:12

29 June 2015, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announced that together with its alliance partner, VirtualScopics, Inc. (Ticker: VSCP) ('VirtualScopics'), it has been awarded contracts with two top 15 pharmaceutical companies, one in metastatic solid tumours and one in a rare neurodegenerative disease. IXICO's TrialTracker™ digital platform will be deployed in both studies to collect and manage imaging data and in the neurodegeneration study, IXICO's Assessa® digital technology will be used to analyse MRI data collected from patients.

The metastatic solid tumour study will make use of VirtualScopics extensive expertise applying FDG-PET (Fludeoxyglucose PET) to measuring disease progression in oncology and will involve working with imaging centres across North America and Europe. The study is expected to complete in June 2017.

The neurodegeneration study will make use of IXICO's expertise in structural MRI and will involve IXICO working with key opinion leaders across specialist imaging centres throughout North America. As part of this contract, IXICO's Assessa® medical device will utilise its proprietary LEAP methodology to quantify disease pathology in brain regions that are particularly relevant to measuring disease progression and will be applied to MRI data collected from subjects enrolled in the study. The study is expected to complete in January 2018.

Professor Derek Hill, Chief Executive Officer of IXICO, commented: "Our alliance with VirtualScopics continues to be valued by our pharmaceutical partners as we support their clinical trials on a global basis, as evidenced by these two new contract wins. Our TrialTracker™ digital platform provides customers with digital technology combined with operational effectiveness. Furthermore, our involvement with the neurodegenerative disease study demonstrates our ability to broaden our therapeutic expertise and validates the importance of IXICO's technology across a range of brain diseases."

Eric Converse, Chief Executive Officer of VirtualScopics commented: "Winning these two recent studies with IXICO clearly demonstrates the strength of our alliance. We are bringing a viable, stronger imaging choice to the risk averse pharmaceutical industry. The list of studies on TrialTracker™ within VirtualScopics continues to grow with increased momentum. Customers are very pleased with this option. TrialTracker™ is the backbone of our relationship with IXICO and allows us to fully exploit our collaborative offering."

[hedgehog 100] 21/5/2015 20:57

18/05/2015 07:01 UKREG IXICO plc Interim Results

" ... During the six months there was a net cash outflow of GBP1.3million resulting in a cash position of GBP1.95million at 31 March 2015 (H1 2014: GBP3.89million). ... "




At the current rate of cashburn the cash won't last another year.

This suggests the likelihood of a fundraising at a lower level than the current 26.5p.

[jondev] 19/5/2015 18:06

And the price continues to drop like a brick, think it's about time to get rid of this one. Have had enough

[skinny] 18/5/2015 07:31

Expanding clinical trials services and digital healthcare offering

Strong growth in total income and reduction in loss

IXICO plc (AIM: IXI), the brain health company, announces its unaudited interim results for the six months ended 31 March 2015.

Period Highlights
· Extension of two clinical trials in Huntington's Disease, valued at approximately £2.5m over three years
· VirtualScopics alliance delivering commercial value
o Won first joint project for top 15 pharmaceutical company
o License of TrialTracker™ proprietary image data and query management platform
· Partner in the European Prevention of Alzheimer's dementia Initiative (EPAD)
· Strengthened capabilities, technology and IP on healthcare data analytics
· Financial performance underpinned by strong revenue growth of 36% to £1.6m
o Total income (revenue plus other income) up 40% to £2.0m
o Loss reduced by 58% to £0.6m despite increased investment in R&D; Loss per share 4.1p (2014 loss per share 10.5p)
o Cash of £1.95m at 31 March 2015 with second half cash inflows to include committed grant funding

Post-Period Highlights
· Third contract award in Huntington's Disease within 12 months
· Launch of the Project Cygnus digital platform to support patients with the diseases that cause dementia
o IXICO is the lead partner working alongside The Northern Health Science Alliance Network, several NHS Trusts in the North of England and MRC Technology
· UK Government funded project to support accurate differential diagnosis of CNS diseases


Derek Hill, Chief Executive Officer of IXICO, said:
"We have delivered strong growth in our business and made good progress in executing important strategic developments during the period. Our digital technology platforms are opening up new, high value commercial opportunities with existing and new customers in dementia and increasingly, other diseases. The marked top-line growth we have reported arises from both expansion of our clinical trials business and initial contracts from the pharmaceutical sector for our digital healthcare platform. We expect to maintain this momentum and to grow our digital healthcare revenue moving forward.

We look forward to building on this progress to take IXICO into the next phase of its corporate development. We continue to explore opportunities to build critical mass through further partnerships, product licencing and potential merger and acquisition activities."

[mach100] 26/3/2015 10:44

Thanks Hedgehog, yes I meant the finals. IXI seems to be flatlining now. An interesting space but hard to value! Thanks for the link.

[mach100] 25/2/2015 15:34

Any views on the interims? IXI has revenue (but down on 2013) but operating expenses seem quite high. Would be worth it if it hits paydirt. Assessa is not performing well. I am not sure how key Assessa is to the company but it seems to be floundering. Dementia is a key area so I am definitely interested in IXI. I would love to know where the floor is though and the spread is really off-putting

[loobrush] 28/11/2014 17:43

I am not sure but end of year was end september. Last year there was update mid December and results February. But this year could be different but I am expecting something in two weeks or so.

[michaelfox] 28/11/2014 15:41

Any ideas when 30 Sep financials are due? Thanks

[loobrush] 27/11/2014 20:36

I agree with your comments and what may be of particular interest is that they have stated they are looking for acquisitions in the same field. As they have millions in cash and could soon be in profit, they would have cash available to make investments say in a drug discovery company that combats dementia etc.
I would not rule out further purchases of shares by funds wanting to get into this segment of healthcare either.

[michaelfox] 27/11/2014 19:28

Loobrush...perhaps it's the history of this company or more specifically the predecessor company that makes others cautious. Have to say, prospects, it's specialist space in the market, partnerships and hugely importantly the management team make this a very interesting share indeed. I think results due in Dec (?) so should get a picture on financials but the July update painted a very positive picture. Looking forward to it and regard this as an opportunity to accumulate. Investor records show 41% of shares not in public hands then a further 40% held by asset managers and Imperial. So perhaps share movement is a result if a lack of liquidity. Anyhow all points to interesting times.

[loobrush] 27/11/2014 12:27

Well not many seem interested in this share at the moment but as a healthcare share and in dementia they should be.
Clearly undervalued, I expect that an analyst will pick this up soon, maybe when results out.
Directors recently awarded options.
The award of options under the Scheme are over the ordinary shares in the Company and are exercisable at an exercise price of 49.0p subject to various conditions. For each Executive Director, half of the options will not vest earlier than one year from the date of grant and will be subject to absolute share price performance. The options will vest in equal tranches on the first, second the third anniversary of grant with an annual hurdle of 10% share price appreciation being required in any 12 month period. The other half of the options are subject to a number of enhanced performance criteria including a more than doubling of the share price in a twelve month period or other corporate and strategic goals being met.
So Directors have options which are only exercisable if share price goes up and minimum level to get some is 49p+10% = 54p -that's 35% above today's price.
Also some of the options subject to DOUBLING SHARE PRICE
That's a big incentive to get the company really moving.

[loobrush] 26/11/2014 09:07

See rns
Contract of £2.5 million over 3 years to add to their existing contracts. Company less cash valued AT ONLY about £2 million.
They are really pulling in the business and this is only the start. This news makes this a raging buy should be at least twice this price. Being at the forefront of Dimentia research, the price wont stay here for long once people cotton on to the potential and I think that they may well acquire some other businesses to speed up growth.Got to be at least 100% upside here way undervalued.

[ewads] 23/11/2014 11:36

Out of 15mill shares in circulation, there have been greater sells than buys since Phytoharm bought in. There doesn't appear to be any enthusiasm for investors here.

[loobrush] 22/11/2014 13:48

lse board
Ixico has dropped to a low for the year at 35p and in my view is due for a big bounce.
The company is one of two on the market involved in Dementia diagnosis and has recently launched a dimentia diagnostic kit which it is promoting.
With the immense focus on this disease by the government this could turn into really big business
Directors were recently granted options at 49p with the ability to take these up subject to increasing the share price from 49p.
The company has been doing very well lately too. An update is due from the company in December
Cash in the bank of over £3 million and company valued at only £5.25 million inc cash this has got to be a steal.
Was as high as 120p has dropped a lot.

[mozii] 16/9/2014 19:08

Any news expected soon here?

[tegs] 31/7/2014 16:31

So now we know it was The Capital Fund that sold all their holding, which has got to be good news as someone else must have bought.

RNS Number : 9377N

IXICO plc

31 July 2014



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
---------------------------------------------------------------------------------------

1. Identity of the issuer or the underlying Ixico PLC
issuer
of existing shares to which voting rights
are
attached:
------------------------------------------------- ------------------------------------
2 Reason for the notification (please tick the appropriate box or boxes):
---------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
------------------------------------------------------------------------------ -------
An acquisition or disposal of qualifying financial instruments
which may result in the acquisition of shares already issued to
which voting rights are attached
------------------------------------------------------------------------------ -------
An acquisition or disposal of instruments with similar economic
effect to qualifying financial instruments
------------------------------------------------------------------------------ -------
An event changing the breakdown of voting rights
------------------------------------------------------------------------------ -------
Other (please
specify):
------------------ ---------------------------------------------------------- -------
3. Full name of person(s) subject The Capital Fund No 1 LP
to the
notification obligation:
------------------------------------------ -------------------------------------------
4. Full name of shareholder(s)
(if different from 3.):
------------------------------------------ -------------------------------------------
5. Date of the transaction and date 28(th) July 2014
on
which the threshold is crossed
or
reached:
------------------------------------------ -------------------------------------------
6. Date on which issuer notified: 31(st) July 2014
------------------------------------------ -------------------------------------------
7. Threshold(s) that is/are crossed Held 4.72% now holding is Nil .
or No longer have a notifiable interest.
reached:

[tegs] 30/7/2014 10:31

Looking at the prints 680,023 sold on Monday 28th July at 37 pence suggests a fund has sold their holding. With 14.95 million shares in issue this suggest a holder of 4.54% therefore the trade has to be notified to the market, we will then see who the seller was and if they have cleared out all their shares.

[mach100] 30/7/2014 09:34

Strange trading in the last week. Massive dumping at well under the bid. Yesterday a flurry of trades at almost full ask like it had been tipped somewhere. But today down on a few trades. I thought the overhang had been cleared but wonder has this further to fall? Reckon it is good value though if you can call the bottom.